European Commission claims pharma competition success
The proportion of problematic patent settlements in the pharmaceutical industry has fallen, even though the number of settlements has grown, according to the European Commission
In a statement published on January 31, the Commission said that its third annual survey had found that 11% of antitrust settlements were potentially problematic from an antitrust point of view, compared to 21% when the pharmaceutical sector enquiry was conducted in 2008 to 2009.
That came as the total number of settlements reached 120 in 2011,...
Please log in
to read the rest of this article. New to Managing Intellectual Property?
Take advantage of one week’s FREE access
and become a Managing IP member today. It’s free to join and the benefits start straight away.
Please make sure you log in to read the rest of the article.
Join us nowGain 7 days FREE access when you register now.